Compare PNW & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNW | CYTK |
|---|---|---|
| Founded | 1985 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 10.7B |
| IPO Year | 1994 | 2004 |
| Metric | PNW | CYTK |
|---|---|---|
| Price | $101.63 | $64.21 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 17 | 22 |
| Target Price | $102.93 | ★ $109.40 |
| AVG Volume (30 Days) | 990.9K | ★ 2.0M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | ★ 3.57% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.70 | N/A |
| Revenue | ★ $5,339,939,000.00 | $13,368,000.00 |
| Revenue This Year | $5.16 | $72.47 |
| Revenue Next Year | $5.71 | $179.45 |
| P/E Ratio | $60.06 | ★ N/A |
| Revenue Growth | ★ 4.20 | N/A |
| 52 Week Low | $86.18 | $54.30 |
| 52 Week High | $111.16 | $88.31 |
| Indicator | PNW | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 69.63 | 43.08 |
| Support Level | $97.26 | $63.96 |
| Resistance Level | $103.70 | $67.07 |
| Average True Range (ATR) | 1.82 | 1.99 |
| MACD | 1.02 | 0.33 |
| Stochastic Oscillator | 85.12 | 61.26 |
Pinnacle West is a holding company whose principal subsidiary is Arizona Public Service, a vertically integrated electric utility serving approximately 1.4 million customers across a 35,000-square-mile territory in central Arizona, including the Phoenix area. APS owns or leases 6.5 gigawatts of power generation capacity, including a 29% ownership stake in one of the largest nuclear plants in the US, Palo Verde. Half of the electricity that APS supplies to customers comes from clean energy sources, including nuclear.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.